4-((S)-2-amino-5-tert-butoxycarbonyl-pentanoyl)-piperazine-1-carboxylic acid ethyl ester | 913952-28-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-((S)-2-amino-5-tert-butoxycarbonyl-pentanoyl)-piperazine-1-carboxylic acid ethyl ester
• 英文别名: ethyl 4-[(2S)-2-amino-6-[(2-methylpropan-2-yl)oxy]-6-oxohexanoyl]piperazine-1-carboxylate
• CAS: 913952-28-0
• 化学式: C₁₇H₃₁N₃O₅
• 分子量: 357.45
• InChiKey: KBZYKMGIMUVJDK-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  25
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-hydroxy-1-phenyl-1H-pyrazole-3-carboxylic acid 、 4-((S)-2-amino-5-tert-butoxycarbonyl-pentanoyl)-piperazine-1-carboxylic acid ethyl ester 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 4-{(S)-5-tert-butoxycarbonyl-2-[(5-hydroxy-1-phenyl-1H-pyrazole-3-carbonyl)amino]pentanoyl}piperazine-1-carboxylic acid ethyl ester
  参考文献：
  名称：

  [EN] PYRAZOLE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS
  [FR] DÉRIVÉS DE PYRAZOLE-CARBOXAMIDE UTILES EN TANT QU'ANTAGONISTES DE P2Y12

  摘要：

  公开号：

  WO2009080227A3
• 作为产物：
  描述：

  4-((S)-2-benzyloxycarbonylamino-5-tert-butoxycarbonylpentanoyl)piperazine-1-carboxylic acid ethyl ester 在 palladium on carbon 氢气 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 4-((S)-2-amino-5-tert-butoxycarbonyl-pentanoyl)-piperazine-1-carboxylic acid ethyl ester
  参考文献：
  名称：

  [EN] PYRAZOLE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS
  [FR] DÉRIVÉS DE PYRAZOLE-CARBOXAMIDE UTILES EN TANT QU'ANTAGONISTES DE P2Y12

  摘要：

  公开号：

  WO2009080227A3

文献信息

• Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists
  申请人：Caroff Eva

  公开号：US20080194576A1

  公开（公告）日：2008-08-14

  The invention relates to 4-aminocarbonyl-pyrimidine derivatives and their use as P2Y 12 receptor antagonists in the treatment and/or prevention and/or treatment of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

  该发明涉及4-氨基甲酰基嘧啶衍生物及其作为P2Y12受体拮抗剂在治疗和/或预防外周血管、内脏-、肝脏-和肾脏血管、心血管和脑血管疾病或与血小板聚集有关的疾病或状况的用途，包括在人类和其他哺乳动物中的血栓形成。
• QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS
  申请人：Nazaré Marc

  公开号：US20100135999A1

  公开（公告）日：2010-06-03

  The present invention relates to compounds of the formula I, in which R 1 ; R 2 ; R 3 ; R 4 ; R 5 ; R 6 ; Z; A; B; E; X; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及公式I的化合物，其中R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G和M具有所述声明中指示的含义。公式I的化合物是有价值的药理活性化合物。它们对血小板具有强烈的抗聚集作用，从而具有抗血栓作用，适用于治疗和预防心血管疾病，如血栓栓塞病或再狭窄。它们是血小板ADP受体P2Y12的可逆拮抗剂，通常适用于存在不良激活血小板ADP受体P2Y12的情况，或者治愈或预防需要抑制血小板ADP受体P2Y12的情况。此外，本发明还涉及制备公式I化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制药制剂。
• Pyrazole-carboxamide derivatives as P2Y12 antagonists
  申请人：Nazaré Marc

  公开号：US08598179B2

  公开（公告）日：2013-12-03

  The present invention relates to compounds of the formula I, wherein R1; R2; Z; A; B; D; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable, e.g., for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及式I的化合物，其中R1；R2；Z；A；B；D；Q；J；V；G和M具有所述要求中指示的含义。式I的化合物是有价值的药理活性化合物。它们展示出强烈的抗血小板聚集作用，因此具有抗血栓作用，并适用于治疗和预防心血管疾病，如血栓栓塞性疾病或再狭窄。它们是血小板ADP受体P2Y12的可逆拮抗剂，通常适用于存在不必要的血小板ADP受体P2Y12激活或需要抑制血小板ADP受体P2Y12的治疗或预防的情况。此外，本发明还涉及制备式I化合物的方法，它们的用途，特别是作为药物中的有效成分，并含有它们的制药制剂。
• PYRAZOLE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS
  申请人：NAZARÉ Marc

  公开号：US20110039829A1

  公开（公告）日：2011-02-17

  The present invention relates to compounds of the formula I, wherein R1; R2; Z; A; B; D; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable, e.g., for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及公式I的化合物，其中R1; R2; Z; A; B; D; Q; J; V; G和M具有所述声明中指示的含义。公式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血小板聚集作用，从而具有抗血栓作用，并适用于治疗和预防心血管疾病，如血栓栓塞性疾病或再狭窄。它们是血小板ADP受体P2Y12的可逆拮抗剂，并且通常适用于存在不良激活血小板ADP受体P2Y12的情况或者治愈或预防需要抑制血小板ADP受体P2Y12的情况。本发明还涉及公式I的化合物的制备过程，它们的使用，特别是作为药物中的活性成分，以及包含它们的制药制剂。
• PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP1893634A2

  公开（公告）日：2008-03-05